If the cost of editing is not exorbitant (i.e. is lower than the average per-capita cost of paying for the condition being edited away), healthcare providers would be incentivized to pay for the editing to reduce their costs.

The incentives are obviously stronger in single-payer countries, but even in the US you could imagine an insurance company that competed on lower premiums conditional upon certain gene edits being applied to covered children.